The goal of Immudel-gp120, the anti-AIDS drug we're working on, is to stop "bystander" T4 cell death.

Immudel-gp120 has been designed to change the immune system's reaction to HIV in a way that disrupts HIV' destructive interaction with healthy T4 cells. It is expected to "reset" the immune system to the relatively healthy state that it was in a couple of weeks after initial infection.

Since the drug is a protein, it will have to be injected. We expect that it will have to be taken at least every month, but less than once a week.

Our early pilot safety tests suggest essentially no side effects, except for perhaps a little soreness around the injection site for a few hours. However, we won't really know how humans react to the drug until after clinical trials begin.

No. Immudel-gp120 is in the earliest stages of pre-clinical testing, and it will be at least four years before it is on the market. When Immudel-gp120 is available, information about it will be posted on this site.

Institute for Applied Biomedicine also maintains a list of people who want to be contacted when clinical trials for Immudel-gp120 begin. You can send your name, e-mail address, and other contact information to and request to join the Clinical Trials Notification Program.

Anyone can join this informational program. You do not have to be HIV+. You will not be obligated to participate in the clinical trials. The program will only send you a letter to let you know when clinical trials begin. Information sent to this program is kept strictly confidential.

No!

We rely on donations to fund our research. It is true that the more funding we have, the faster our research work gets done. Institute for Applied Biomedicine is a 501(c)(3) public charity, and donations are tax-deductible for U.S. income tax purposes as allowed by law.

However, donors get no special advantages or priority because of their gifts. The team making decisions about clinical trials and drug distribution will have no information about who is a donor and who is not.